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Osmotic minipumpParkinson's disease (PD) is a progressive neurodegenerative disorder characterized by a prominent loss of
nigrostriatal dopamine (DA) neurons with an accompanying neuroinﬂammation. The peptide angiotensin II
(AngII) plays a role in oxidative-stress induced disorders and is thought to mediate its detrimental actions
via activation of AngII AT1 receptors. The brain renin-angiotensin system is implicated in neurodegenerative
disorders including PD. Blockade of the angiotensin converting enzyme or AT1 receptors provides protection
in acute animal models of parkinsonism. We demonstrate here that treatment of mice with the angiotensin
converting enzyme inhibitor captopril protects the striatum from acutely administered 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyrine (MPTP), and that chronic captopril protects the nigral DA cell bodies from degeneration
in a progressive rat model of parkinsonism created by the chronic intracerebral infusion of 1-methyl-4-
phenylpyridinium (MPP+). The accompanying activation of microglia in the substantia nigra of MPP+-treated
rats was reduced by the chronic captopril treatment. These ﬁndings indicate that captopril is neuroprotective for
nigrostriatal DAneurons inboth acute and chronic rodent PDmodels. Targeting the brain AngII pathwaymay be a
feasible approach to slowing neurodegeneration in PD.
© 2013 The Authors. Published by Elsevier Inc.Open access under CC BY-NC-ND license.Introduction
Parkinson's disease (PD) is a devastating progressive neurodegener-
ative disorder characterized by severe loss in motor function due to the
extensive degeneration of the nigrostriatal dopamine (DA) neurons.
The exact cause(s) of neurodegeneration remain to be determined but
defective mitochondria, oxidative stress and inﬂammatory responses
likely play prominent roles (Appel et al., 2009; German et al., 2012;
Hirsch and Hunot, 2009).
Oxidative stress and inﬂammation are major contributors to hyper-
tension and cardiovascular disease. The peptide angiotensin II (AngII)
plays a prominent role in cardiovascular disease and other oxidativeS grant award (R21NS058329),
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arch Building, Rm 142, Rutgers,
n Medical School, Piscataway,
salla).
. Open access under CC BY-NC-ND licestress-related disorders. AngII, via actions on the AngII AT1 receptors,
is a potent inducer of reactive oxygen species (ROS), oxidative stress
and inﬂammation in many cells including immune cells and neurons
(Bernstein et al., 2013; Coleman et al., 2013; Labandeira-Garcia et al.,
2012). This occurs predominantly by way of AT1 receptor activation of
the NADPH-oxidase (Nox) system with formation of superoxide and
subsequently other oxidant molecules (Dikalov, 2011).
The brain possesses a complete renin-angiotensin system (RAS),
reviewed in (Labandeira-Garcia et al., 2012; Saavedra, 2012). Most of
the actions of AngII in the brain are mediated by AngII AT1 receptors
(AT1R) and AT2 receptors (AT2R) which reside on neurons and non-
neuronal cells. Much of what is known about the brain RAS has evolved
from research on its role in cardiovascular regulation by the brainstem
nuclei. Considerably less is known about its function in other brain
regions. However, RAS components are found throughout the brain,
particularly in the basal ganglia (McKinley et al., 2003). AngII is formed
by the sequential activity of renin and the angiotensin-converting
enzyme (ACE) on the precursor angiotensinogen (McKinley et al.,
2003). ACE activity is considerably higher in the substantia nigra (SN)
and striatum as compared with other brain regions and AngII receptors
co-localize with nigral DA neurons (Arregui and Barer, 1980; Joglar
et al., 2009; Rodriguez-Perez et al., 2010). AngII alters DA function by
modifying striatal DA synthesis, storage and release (Dwoskin et al.,nse.
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2012). Thus, AngII actions impact DA function.
The brain RAS is implicated in neurodegenerative disorders in-
cluding PD, stroke, and Alzheimer's disease (AD) (Saavedra, 2012). In
humans, ACE activity is increased in the cerebrospinal ﬂuid of PD and
AD patients which is thought to reﬂect a response to increased brain in-
ﬂammation (Konings et al., 1994). A genetic polymorphism in the ACE
gene is associatedwith increased risk of PD (Lin et al., 2002, 2007). In an-
imal models, pharmacological studies document a role for AngII in me-
diating inﬂammation and damage through the AT1 receptor (Benicky
et al., 2009; Marchesi et al., 2008; Saavedra et al., 2006; Sanchez-
Lemus et al., 2009; Schulz and Heusch, 2006). Blockade of ACE, using
captopril or perindopril has been shown to exert neuroprotective effects
in the striatum and the SN of mice treated acutely with 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) (Jenkins et al., 1999; Munoz
et al., 2006) or in rats receiving an acute intracerebral (icv) infusion of
6-hydroxydopamine (Kurosaki et al., 2004; Lopez-Real et al., 2005).
The purpose of the present study was to examine the neuroprotec-
tive effects of theACE inhibitor captopril in an acute aswell as a progres-
sive rodent model of PD. While there is evidence that acute treatments
with ACE inhibitors or AngII AT1R antagonists are neuroprotective in
acute treatment paradigms, it is not known if these compounds can pro-
tect in a chronic progressive PDmodel. A progressive PDmodel was cre-
ated by chronic intracerebral ventricular (icv) infusion of 1-methyl-4-
phenylpyridinium (MPP+) in the rat. In this model, there is a progres-
sive loss of striatal DA and tyrosine hydroxylase (TH) and of nigral DA
neurons (Sonsalla et al., 2012; Yazdani et al., 2006). We also extended
our studies to examine ACE activity, antioxidant pathways and microg-
lia response in these PD models. Our ﬁndings demonstrate that capto-
pril provides neuroprotection in both animal models, and suggest that
reducing themicroglial responsemay, in part, underlie its neuroprotec-
tive properties.Methods
Animals
Male Swiss-Webster mice (Taconic Farms, Germantown, NY)
weighing 30–35 g were used for the MPTP studies. Male Sprague–
Dawley rats (weighing ~300 g at the beginning of the study) (Taconic
Farms, Germantown, NY) were used for the MPP+ infusion studies.
All animals were maintained on a 12-h light–dark cycle with food and
water available ad libitum. All experiments were performed in accor-
dance with the National Institutes of Health Guide for the Care and
Use of Laboratory Animals and were approved by the animal care com-
mittee of Rutgers-RWJMS. The number of mice used ranged from 4 to
8 mice/group and the number of rats for the neurochemical studies
ranged from 8 to 10 rats/group. The actual number/group is indicated
in the ﬁgure legends.MPTP treatment in mice
Micewere treated with (Albers et al., 1996) vehicle/vehicle (saline);
(Appel et al., 2009) captopril/vehicle (single s.c. injection of captopril at
20 mg/kg 30 min before vehicle); (Arregui and Barer, 1980) vehicle/
MPTP (single acute s.c. injection of 30 mg/kg MPTP as free base) and
(Benicky et al., 2009) captopril/MPTP (single s.c. injection of captopril
20 mg/kg 30 min before MPTP). Mice were euthanized 15 h, 3 days or
7 days after treatment. We and others have shown that the mouse
MPTP model produces extensive loss of striatal nerve terminals and of
nigral DA neurons (Albers et al., 1996; German et al., 1996; Giovanni
et al., 1994; Liang et al., 1996). The dose of captopril was selected
based on previous studies (Munoz et al., 2006). MPTP-HCl and captopril
were from Sigma-Aldrich.Surgeries and MPP+ infusions in rats
Vehicle (sodium-iodide) orMPP+-iodide (Sigma-Aldrich) dissolved
in sterile saline was infused into the left cerebral ventricle through a
cannula which was connected by tubing to an Alzet osmotic minipump
(model 2ML4) implanted subcutaneously as previously described
(Sonsalla et al., 2012; Yazdani et al., 2006; Zeevalk et al., 2007). Stereo-
taxic cannula placement was at coordinates relative to bregma: anterior
−0.5 mm, lateral left+1.4 mm,depth−3.9 mm(Paxinos andWatson,
1986). Stereotaxic surgery and minipump placement were performed
under ketamine/medetomidine anesthesia (100 mg/kg and 0.6 mg/kg,
respectively). Following the surgical procedure, the rats were treated
with atipamezole (1 mg/kg s.c.) to reverse anesthesia. Rats also re-
ceived rimadyl (5 mg/kg s.c., before surgery and 24 h later), and ampi-
cillin administered under anesthesia (100 mg/kg i.m.) and again 24 h
later (50 mg/kg, s.c.). MPP+-iodide was infused at a dose of 75 μg/day
for 28 days with a drug delivery rate of 2.5 μl/h. Animals were killed
27–28 days after surgery. Captopril was administered twice daily
(7.5 mg/kg/injection s.c.) starting on the day of MPP+ infusion.Neurochemistry
In rats used for neurochemistry and midbrain DA cell counts, brains
were rapidly removed and sectioned at mid-hypothalamus. Left and
right striata were dissected from the forebrain, weighed and frozen at
−80 °C until analyzed. The hindbrain containing the SNwas immersion
ﬁxed in paraformaldehyde for immunohistochemistry. In mice, the
striata were dissected from the brain and frozen until analyzed. Mono-
amines and metabolites were measured using HPLC/EC and TH protein
was measured with an ELISA technique as is routinely performed in
our laboratory (Sonsalla et al., 2012). ACE activity was measured in tis-
suehomogenates as described previously (Schwager et al., 2006); gluta-
thione peroxidase (GPx) activity was measured by the Sigma assay kit
(product number CGP-1); superoxide dismutase (SOD) was measured
by the Sigma assay kit (product number 19160) and proteasomal ac-
tivity was measured by the proteasome 20S assay (product number
BML-AK740-0001; Enzo Life Sciences).Brain MPP+ measurements
Mice received vehicle or captopril (20 mg/kg s.c.) 30 min before
MPTP and were euthanized 1.5 h after MPTP administration. Striata and
cortexwere dissected out and frozenuntil assayed.MPP+concentrations
weremeasured using procedures established in our laboratory (Giovanni
et al., 1991).Immunohistochemistry for nigral DA cells and activated microglia
The hindbrain in rats was used for performing SN TH+ cell counts
using immunohistochemical methods as described previously (Sonsalla
et al., 2012; Yazdani et al., 2006). Brieﬂy, 30-μm-thick coronal sections
were cut through the entire rostral–caudal extent of the SN. Every
fourth section through the SN was stained with an antibody against TH
(1:4000; Protos Biotech Corp.) to identify the DA neurons. Unbiased ste-
reology techniqueswere used to count TH+cells in the SN as previously
described (Sonsalla et al., 2012).
Some rats were transcardially perfused for evaluating microglial
response and TH staining in both the striatum and the SN as previously
described (Sonsalla et al., 2012). Cryostat sections from the striatumand
the SNwere immunostained with an antibody against ED1 (1:100; AbD
Serotec) to identify activated microglia. Some sections were double
labeled by immunoﬂuorescence for TH and ED1. Digital photographs
were taken using a Zeiss Axioplanmicroscope (Carl Zeiss, Inc.) equipped
with an epi-ﬂuorescence illuminator and Axiovision software.
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StereoInvestigator software (version 9.0. MicroBrightﬁeld Inc.,
Williston, VT) was used to count TH-immunoreactive (TH-IR) SN cells.
Cells were counted with a 40× objective using a Leica DMRE micro-
scope. The cell counting frame was 50 × 50 × 5 μmwith a 2 μm upper
and lower guard zone. A cell was deﬁned as TH-IR somata with a clearly
visible unstained nucleus. The TH cell countswere taken from6 sections,
spaced 4 apart (120 μm) and 200–250 cells were counted in the SN
on the left side of each brain ipsilateral to the lateral ventricular
MPP+ infusion. The SN region was deﬁned according to previous ana-
tomical demarcation in the rat (German and Manaye, 1993).
Statistical analysis
Differences among the means in the MPTP-treated mice were
analyzed using one-way analysis of variance (ANOVA). In rats with a
unilateral lesion, two-way ANOVA was initially used to evaluate the
data. Two-way ANOVA revealed signiﬁcant differences between treat-
ment groups and sides (left lesioned and right non-lesioned sides).
One-way ANOVA on data from the right unlesioned sides of the rats
revealed no signiﬁcant differences across treatment groups allowing
use of one-way ANOVA for comparisons in the left lesioned side
across treatment groups. When ANOVA showed signiﬁcant differences,
comparisons between means were tested by the Tukey–Kramer or
Bonferroni multiple comparisons post hoc test. In all analyses, the null
hypothesis was rejected at the 0.05 level. All values are expressed as
the mean ± SEM.
Results
Captopril attenuatesMPTP-induced loss of striatal DA, DOPAC and TH in the
acute parkinsonian mouse model
To determine a neuroprotective effect of captopril, mice were
treated acutely with captopril and MPTP. Seven days after the acutea
Fig. 1. Captopril treatment attenuates the decreases in striatal DA neurochemistry produced
30 min before MPTP (single 30 mg/kg s.c. injection) and euthanized 7 days later. Results ar
MPTP plus captopril. ap b 0.05 from controls; bp b 0.05 from MPTP group.treatment paradigm, there were signiﬁcant reductions in striatal DA
(−90%), DOPAC (−71%) and TH (−82%) in MPTP-treated mice as
compared to control values (Fig. 1). A single injection of captopril signif-
icantly attenuated the MPTP-induced reduction of DA (−52%), DOPAC
(−51%) and TH (−56%) levels. These ﬁndings show a neuroprotective
effect of captopril in the mouse striatum. Mice treated with captopril
alone had small but signiﬁcant reductions in striatal TH protein and
HVA content.
In mice treated acutely with MPTP, captopril does not modify MPP+
concentrations in the brain, inhibit MAO-B activity in brain homogenates
or prevent uptake of 3H-DA into striatal synaptosomes
Because MPTP requires conversion to the actual neurotoxicant
MPP+ by monoamine oxidase B (MAO-B), we needed to determine
if captopril had any effect on MPP+ formation in the mouse brain, on
MAO-B activity, or on the DA transporter. As shown in Table 1, in
MPTP-treated mice that had been pre-treated with vehicle or captopril,
striatal MPP+ levels were similar. Additionally, MPP+ levels in cortex
were similar in both groups as well although they were approximately
one-third of the amountmeasured in the striatum. Asmight be expected,
MAO-B activity in brain homogenates was not altered by concentrations
up to 1 mM captopril (data not shown). Likewise, captopril, at concen-
trations up to 1 mM, did not impair the uptake of 3H-DA into striatal syn-
aptosomes (data not shown). These ﬁndings indicate that captopril does
not interfere with the formation of MPP+ in the brain or of its accumu-
lation within DA neurons.
In the progressive rat model produced by chronic MPP+ infusion, captopril
attenuates the loss of nigral TH+ cells
We used a rat model in which MPP+ is chronically infused into the
left cerebral ventricle. Rats were euthanized at 27–28 days after pump
implantation. At this time point, TH+ cells in the ipsilateral SN of
rats infused with MPP+were reduced by 69% (Table 2). Chronic treat-
ment of the MPP+-treated rats with captopril (7.5 mg/kg, twice daily)a
a, b
by MPTP treatment in mice. Mice were treated with vehicle or captopril (20 mg/kg s.c.)
e the mean ± SEM of n = 4 for controls and captopril alone, and n = 8 for MPTP and
Table 1
Captopril does not alter MPP+ formation from MPTP in mouse brain. Mice were treated
with captopril (20 mg/kg s.c.) 30 min before MPTP (30 mg/kg s.c.) and were euthanized
1.5 h after MPTP administration. Results are the mean MPP+ concentration ± SEM
from 4 mice/group.
Treatment MPP+ (μg/g tissue)
Striatum Cortex
Vehicle + MPTP 7.9 ± 0.7 2.4 ± 0.4
Captopril + MPTP 7.4 ± 0.9 2.3 ± 0.5
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Fig. 2. Captopril does not alter weight gain in rats receiving icv MPP+. Results are the
average weight of rats treated with vehicle, MPP+ or captopril/MPP+ (8–10 rats/group).
No signiﬁcant differences in weights were observed between the groups at any of the time
points. Moreover, the slopes of the lines are similar for all three groups.
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that captopril provides neuroprotection to DA cell bodies in the chronic
progressive MPP+ model. Counting of the Nissl-stained SN neurons
in these animals has conﬁrmed that this is loss of neurons and not just
a loss of TH staining in the SN of the MPP+-treated rats (Yazdani
et al., 2006).
Captopril does not affect weight gain in rats treated chronically withMPP+
Shown in Fig. 2 are the weight gains in rats treated with vehicle,
MPP+ and captopril/MPP+. Captopril did not signiﬁcantly affect
weight gain in the rats. While there was a slight loss of weight in all
three groups during the ﬁrst few days, this is a result of the surgical pro-
cedure. It can be seen that the slope of the lines for all 3 groups is similar,
indicating that the rate of weight gain in the rats was similar across
the groups. These data indicate that neither MPP+ nor captopril had
adverse effects on weight gain.
In the chronic progressive parkinsonianmodel, captopril does not attenuate
MPP+-induced loss of striatal TH and DA in rats
In contrast to the protection seen in the SN, captopril treatment did
not signiﬁcantly modify the MPP+-induced neurochemical changes in
the striatum. The chronic icv MPP+ infusion produced signiﬁcant uni-
lateral reductions in the contents of TH (−34%), DA (−54%), DOPAC
(−76%), and HVA (−44%) in the left striatum (ipsilateral to icv infu-
sion) of the rats (Fig. 3). Chronic captopril treatment did not signiﬁcantly
modify the MPP+-induced reductions. Moreover, serotonin was not
reduced by MPP + treatment, demonstrating the selectivity of this
dose of MPP+ toward DA neurons as we have previously reported
(Sonsalla et al., 2012; Yazdani et al., 2006). Striatal TH and DA are not
reduced in sham-treated rats, indicating that cannula placement into
the ventricle does not damage DA nerve terminals (data not shown;
see also Yazdani et al., 2006). Taken together, these data indicate that
captopril protection is exerted at the level of the cell bodies in the SN.
In the chronic progressive parkinsonian model, captopril attenuates
microglia response in the SN of MPP+-treated rats
To evaluate the microglial response, brain sections containing the
SN or striatumwere immunostained with an antibody to ED1, which de-
tects activatedmicroglia, and counterstainedwith a THantibody to detect
DA neurons. In these experiments, we examined immunoﬂuorescence inTable 2
Captopril reduces MPP+-induced loss of TH + neurons in substantia nigra (SN) of rats
Rats received continuous icv infusion of MPP+ (75 μg/day, left cerebral ventricle) for
27–28 days and were killed at the end of the infusion period. Some rats were injected
with captopril (twice daily, 7.5 mg/kg/injection s.c.) for the duration of treatment.
Results are the mean number of TH+ neurons in the left SN ± SEM. N/group is in
parentheses. ap b .001 vs. naives; bp b .01 vs. MPP+ group.
Treatment TH+ cells
Naive 7323 ± 312
MPP+ 2266 ± 590a
Captopril/MPP+ 5601 ± 469a,btwo rats treated with MPP+ and two rats treated with captopril/MPP+.
Immunohistochemical staining revealed robust ED1 immunostaining in
the lesioned striatumof theMPP+-treated rats especially near the ventri-
cle (Fig. 4A). Very few ED1 immunostained cells are seen in the right stri-
atum, consistent with the lack of damage in the non-lesioned striatum.
Also, in the right unlesioned striatum, there is intense TH immunostain-
ingwhereas in the left lesioned striatum, TH immunostaining ismarkedly
reduced. In rats treatedwithMPP+and captopril, the ED1 immunostain-
ing in cells in the left striatumwas similar to that seen in rats treatedwith
only MPP+ (data not shown). In the SN, ED1 immunostained cells were
prevalent in the lesioned side of MPP+-treated rats (Fig. 4B). In rats
treated with MPP+ and captopril, there were markedly fewer ED-1 im-
munostained cells. We also examined the striatum for expression of the
microglia marker Mac-1 and the astrocytic marker GFAP. MPP+ treat-
ment produced a signiﬁcant increase in GFAP and Mac-1 expression
(~3-fold), which was not modiﬁed by captopril treatment (data not
shown). While further studies are needed to explore the microglia re-
sponse, the activationofmicroglia in the SNof the captopril/MPP+-treat-
ed rats appears much less than that in the MPP+-treated rats.
Acute treatment of mice with MPTP produces transient elevation in striatal
angiotensin converting enzyme (ACE) activity
To determine if striatal damage modiﬁes the activity of ACE or of
antioxidant enzymes, we assayed the activities of ACE, glutathione per-
oxidase (GPx), superoxide dismutase (SOD) and proteasome 20S inTH DA DOPAC HVA 5HT
0
50
Lesioned side
%
 C
o
aa
a
a
a
a
Fig. 3. Captopril treatment does not modify MPP+-induced changes in striatal DA neuro-
chemistry. Data are the mean ± SEM presented as percent of control (n = 5 naives),
MPP + (n = 10), and captopril/MPP+ (n = 10) rats. ap b 0.05 from controls.
Fig. 4. Captopril reduces the microglia response in the SN ipsilateral to the i.c.v. MPP+ infusion. Photomicrographs are from one of two rats evaluated in each group. ED-1 staining for
macrophages/microglia is in red. TH+ staining for DA neurons andﬁbers is in green. Panel 4A. Note intense ED-1 staining in the left lesioned striatumof theMPP+-treated rat but absence
of staining in the right striatum. Also note reduced TH+ immunostaining in lesioned side. Panel 4B. Representative photomicrographs of the lesioned SN from one of two rats treatedwith
MPP+ and from one of two rats treated with captopril and MPP+. Bottom photomicrographs are at a higher magniﬁcation. Note the large number of ED-1 stained microglia in the
lesioned SN and the fewer ED-1 stained cells in the lesioned SN of the rat treated with MPP+ and captopril.
380 P.K. Sonsalla et al. / Experimental Neurology 250 (2013) 376–383the striatum at early time points after MPTP administration. As shown
in Fig. 5, ACE activity was elevated by 43% at 15 h but had returned to
control values by 3 days afterMPTP treatment. This treatment paradigm
had little effect on GPx, SOD or proteasomal function (data not shown)
although DA was signiﬁcantly reduced at 15 h (50%) and 3 days (74%)
after MPTP administration, indicating that the MPTP treatment pro-
duced a substantial DA lesion.
Discussion
Here we demonstrate that acute captopril treatment attenuates the
reduction of striatal DA measures produced by acute MPTP treatment
in themouse.We also show that the chronic treatment of rats with cap-
topril attenuates the loss of nigral DA cell bodies in the progressive
MPP+ rat model of parkinsonism. The reduced loss of TH+ neuronsin the captopril/MPP+ treated rats was accompanied by a reduced mi-
croglia response in the SN in these rats. These data indicate that
captopril is protective for DA neurons in an acute model as well as in a
chronic progressive mode of parkinsonism. Furthermore, ACE activity
is transiently increased in mice treated acutely with MPTP although
no discernible changes in the antioxidant enzymes (GPx, SOD) or
proteasomal activity were seen at these early time points.
Our data demonstrate that blocking ACE activity with captopril
provides good protection in the striatum and SN against the neurotoxic
effects of MPTP/MPP+. The extent of striatal protection by captopril
in themice treated acutely with MPTP in our study is similar to that ob-
served byMunoz et al. (2006)whoused the same doses of captopril and
MPTP per day but extended their treatment paradigm to 5 days. In their
experiments nigral DA cell losswas reduced from ~50% inMPTP-treated
mice to only ~24% in mice treated with captopril and MPTP (Munoz
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Fig. 5.ACE activity inmouse striatum is signiﬁcantly increased afterMPTP treatment.Mice
were treated with a single 30 mg/kg s.c. injection of MPTP and were killed 15 h, 30 h or
3 days later. Results are the mean ± SEM of 6–7 mice/group. ACE activity was increased
at 15 h after MPTP treatment, ap b 0.05 from controls.
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produced protection in the SN that was similar to that seen in the
mouse MPTP studies (e.g., from a 70% reduction in TH+ cells in rats
treated with only MPP+ to a 24% loss in rats treated with captopril
and MPP+; see Table 2). However, in the chronic progressive MPP+
rat model, captopril did not attenuate striatal reductions in TH, DA or
its metabolites as it did in theMPTP treatedmouse (Figs. 1, 3). A similar
ﬁndingwas observed in our recentwork showing neuroprotectionwith
caffeine (Sonsalla et al., 2012). Chronic caffeine treatment in the drink-
ing water provided protection to nigral cell bodies but not striatal DA
terminals in the progressive MPP+ model. Reasons for this disparity
in the striatum of the acute MPTP mouse model and the progressive
MPP+ model may reﬂect the acute vs. chronic administration para-
digms for the neurotoxicant and captopril and/or the mode of adminis-
tration of the neurotoxicant (systemic s.c. MPTP vs. icv MPP+). It
may also be possible that with the icv route of MPP+ administration,
the striatum is exposed to much higher MPP+ concentrations than
the SN, concentrations that overwhelm all antioxidant pathways. Addi-
tionally, the striatal DA terminals may be more vulnerable than the ni-
gral DA cell bodies to toxic insult. The latter possibility is supported by
several examples of pharmacological agents that provide better protec-
tion in the SN than the striatum from systemically administered MPTP
(Carta et al., 2009; Dehmer et al., 2000; Nomura et al., 2011; Pierri
et al., 2005; Yu et al., 2008). Moreover, in micewith targeted mitochon-
drial damage to DA neurons, loss of striatal DAmarkers precedes and is
generally more severe than loss of nigral DA cell bodies (Pickrell et al.,
2011). Impairment of mitochondrial function by MPP+ is a principal
mechanism by which it causes neurodegeneration (Vyas et al., 1986).
MPP+ also impairs mitochondrial transport in DA axons, providing
another mechanism for greater damage in striatal DA axons than in
cell bodies (Kim-Han et al., 2011). Other possibilities include differences
in number, rate and duration of glial cell activation in the two brain
regions or in brain region differences in production of pro- and anti-
inﬂammatory cytokines or other pro- and anti-oxidant molecules. In
a study with rosiglitazone (an agonist at peroxisome proliferators-
activated receptor), there was complete protection of nigral DA neurons
withminimal protection of striatal DA terminals in theMPTP/probenecid
model (Schintu et al., 2009). This protection was attributed to the
marked attenuation of the SN microglia response. Our ﬁndings would
also suggest an attenuation of the microglia response in MPP+-treated
rats receiving captopril. The differential effect of captopril in the striata
of the acute MPTP model and the progressive chronic MPP+ model
needs further study.
Captopril protection is not due to alteredMPTP pharmacokinetics or
impairment of the uptake ofMPP+ into dopamineneurons. In the acute
MPTP mouse model, striatal MPP+ concentrations were not reduced
by captopril treatment indicating its administration to mice did notinterfere with the pharmacokinetics of MPTP or of its conversion by
MAO-B, ﬁndings that are consistent with a previous report (Munoz
et al., 2006). Captopril at concentrations of up to 1 mM did not signiﬁ-
cantly alter MAO-B activity in brain homogenates or prevent 3H-DA
accumulation in striatal synaptosomes (unpublished data). Moreover,
the lack of striatal protection by captopril in the chronic MPP+ rat
model also indicates that captopril or a metabolite did not interfere
with MPP+ uptake by striatal DA nerve terminals.
The mechanism(s) by which ACE inhibition provides neuroprotec-
tion likely involve the reduction of AngII actions on the AT1 receptors.
In parkinsonian models, neuronal loss and neuroinﬂammation are
reduced by pharmacological inhibition or genetic deletion of the AT1
receptor (Garrido-Gil et al., 2012; Grammatopoulos et al., 2007; Joglar
et al., 2009). Excessive AT1R stimulation is associated with enhanced
inﬂammation in both the periphery and the CNSwhere it can cause neu-
ronal damage (Saavedra, 2012).
Considerable evidence suggests that reducing AngII actions on AT1
receptors reduces oxidative stress primarily by impairing Nox activity
and the production of superoxide and other pro-oxidant molecules
(Hernandes and Britto, 2012). AngII activates Nox in neurons by a
mechanism that involves the translocation of the p47phox subunit
from the cytosol to the plasma membrane where it associates with the
membrane components of Nox (p22phox and gp91phox) forming the
active enzyme (Coleman et al., 2013; Garrido and Griendling, 2009).
ReducingAngII effectswithin the basal ganglia could provide protec-
tion via one or more mechanisms of action and via different cell types.
Nigral DA neurons express various subunits of Nox and nearly all DA
neurons express AT1 receptors thus allowing for actions of AngII direct-
ly on DA neurons (Garrido et al., 2013; Grammatopoulos et al., 2007;
Rodriguez-Perez et al., 2010). In a DA cell line (N27 cells), which
expresses Nox, AT1 receptor antagonism reduces MPP+-induced ROS
in a manner similar to that seen with pharmacological inhibition or
siRNA silencing of Nox providing a functional link between AT1 recep-
tors, Nox activity and DA function (Garrido-Gil et al., 2012; Rodriguez-
Perez et al., 2012). Considerable cross-talk exists betweenmitochondria
and Nox with the ROS generated by either source having the capability
to activate ROS production by the other pathway (Dikalov, 2011). This
process becomes particularly detrimental to DA neurons inwhichmito-
chondrial dysfunction occurs, as byMPP+ in animal PDmodels or in PD
patients presenting with dysfunctional mitochondria (Meredith et al.,
2008; Schapira, 2012). One can envision a cycle of events by which
mitochondrial dysfunction leads to increased Nox activity and elevation
of ROS within the DA neurons.
Reducing AngII actions in microglial cells can reduce their activation
state and the production of ROS. Microglial cells are activated by insults
to the brain including injury and neurodegenerative disorders (German
et al., 2012). In this reactive state, they function to clear debris by phago-
cytic engulfment, clear extracellular glutamate to prevent excitotoxicity,
and generate pro-oxidant molecules. However, reactive microglia can
also actively destroy neurons by phagocytosis and the production of
pro-inﬂammatory molecules. AT1 receptors are highly expressed on
activated microglia and AngII via AT1 receptor activation is a powerful
inducer of Nox activity in microglia (Block et al., 2006). Activation of
AT1 receptors on microglia enhances DA cell death in mesencephalic
cultures (Rodriguez-Pallares et al., 2008). Thus, a reduction in AngII ac-
tions on microglia cells could reduce their activation state, reduce the
production of superoxide and other pro-inﬂammatory molecules and
lessen damage to DAneurons. The reduced number of activatedmicrog-
lia in our progressive MPP+ model suggests that captopril may have
exerted at least some of its beneﬁcial actions via effects on microglia.
Astrocyte function can also be modiﬁed by captopril treatment.
Astrocytes are the main source of angiotensinogen, the precursor of
AngII (Milsted et al., 1990). Furthermore, astrocytes maintain extra-
cellular glutamate levels via regulation of the astrocyte glutamate
transporter. In primary neuron–astrocyte cultures exposed to oxygen–
glucose deprivation, blockade of AT1 receptors or gene knockdown
382 P.K. Sonsalla et al. / Experimental Neurology 250 (2013) 376–383improves neuronal viability and reduces the elevation in extracellular
glutamate levels by actions which cause an up-regulation of the gluta-
mate transporter in the astrocytes (Wu et al., 2010). Extracellular nigral
glutamate levels are elevated in animal PD models (Ochi et al., 2004)
and excessive stimulation of the nigral glutamatergic N-methyl-D-
aspartate (NMDA) receptors located on DA neurons can be excitotoxic,
especially to metabolically compromised DA neurons as in the MPP+-
treated rats. Selective blockade of nigral NMDA receptors protects
DA neurons from metabolic stress, indicating the importance of nigral
glutamate and excitotoxicity to DA neurons (Zeevalk et al., 2000).
Further research is needed to determine if reducing AngII improves
astrocytic uptake of glutamate and reduces excitotoxic damage to nigral
DA neurons.
We found striatal ACE activity is increased at 15 h but not at 3 days
afterMPTP. This observation indicates a short-term elevation and return
to normal within hours afterMPTP treatment. Becausemicroglia activa-
tion occurs over several days, it appears that microglia may not be
the source of this increase in ACE activity. Further research is needed
to determine the cell type and the mechanisms for this up-regulation
of ACE activity.
Captopril, other ACE inhibitors, and AT1R antagonists are used in the
treatment of hypertension. A reduction in blood pressure is oftentimes
seen in PD patients. Thus, it remains to be determined if reducing
AngII actions is a reasonable approach for protection of DA neurons
in PD. The doses of captopril used in our studies are about 7.5 fold
higher than the doses used by humans for the control of blood pressure.
In humans, the daily dose of captopril ranges from 20 to 150 mg
(Hilal-Dandan, 2011). A 150 mg dose given to a 70 kg human would
equate to 2 mg/kg/day. In our rats, the daily dose was 15 mg/kg/day,
which is 7.5-fold higher than the recommended highest dose adminis-
tered to humans. The ACE inhibitor perindopril has been tested in PD
patients and has been shown to improve motor function at doses that
have minimal effects on blood pressure; however, long term studies
were not evaluated for preservation of DA neurons (Reardon et al.,
2000). Understanding the mechanism(s) of action of this class of drugs
clearly warrants further investigation.
In summary, captopril treatment provided protection in the acute
MPTP mouse model and the progressive MPP+ rat model. Further re-
search is needed to identify not only themechanism(s) of neuroprotec-
tion but also the cell types that are involved.References
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